Organon & Co.

NYSE:OGN   3:59:50 PM EDT
-0.95 (-3.88%)

Samsung Bioepis and Organon announce FDA approval of citrate-free high-concentration Humira® Biosimilar Hadlima™ (Adalimumab-BWWD)

Published: 08/17/2022 11:44 GMT
Organon & Co. (OGN) - Samsung Bioepis and Organon Announce FDA Approval of Citrate-free High-concentration Humira® Biosimilar Hadlima™ (adalimumab-bwwd).
Organon & Co - Hadlima is Expected to Be Launched on Or After July 1, 2023 by Organon.